The Best Solution to Nonadherence

One of the biggest challenges in treating schizophrenia is patient nonadherence to prescribed medications. Estimates suggest more than 50% of patients are partially or fully nonadherent with their antipsychotic medication regimens.

Long acting injections (LAI) may be the solution to this problem. Janssen Pharmaceutical Companies of Johnson & Johnson recently announced their supplemental New Drug Application (sNDA) submission for paliperidone palmitate 6-month (PP6M), a treatment for adults diagnosed with schizophrenia. PP6M will be the first and only long-acting injectable (LAI) medication for schizophrenia with a bi-annual dosing regimen, if approved.

To read more about this, see Six-Month Long-Acting Treatment for Schizophrenia in the Works.

Dr Gopal is the Head of Development Psychiatry at Janssen R&D (Johnson & Johnson). Follow him on Twitter: ​@sgopal2